Estrogen receptor-negative/progesterone receptor-positive breast cancer has distinct characteristics and pathologic complete response rate after neoadjuvant chemotherapy.

"Declarations Ethics approval and consent to participateThe study was approved by Harbin Medical University and written informed consent was obtained from all study participants before treatment, and the authors confirmed that all the study was conducted in accordance with the contents of the revised 2013 revised Declaration of Helsinki.Informed consent was obtained from all individual participants included in the study. Consent for publicationContaining any form of personal data (including any personal details, images or videos) has been obtained the consent of the parents or legal guardian of the person or the child. Statements of all case reports have been approved for publication. Competing interestsThe authors declare no competing interests. Competing interests The authors declare no competing interests."

"Funding This work was supported by grants from the Natural Science Foundation of China (Grant Number: 81872145)."